CapsoVision Seeks FDA Breakthrough Device Designation for Non-Invasive Pancreatic Cancer Screening Capsule
核心洞察
CapsoVision (搜索) submitted an FDA application on November 6, 2025, requesting Breakthrough Device Designation for its CapsoCam UGI (搜索) capsule endoscopy system to detect early-stage pancreatic cancer (搜索).
The non-invasive pill-sized camera uses panoramic imaging to visualize the duodenal papilla (搜索), where changes may indicate pancreatic abnormalities before symptoms emerge.
Pancreatic ductal adenocarcinoma (搜索) has only an 8% five-year survival rate, with 80% of cases diagnosed at advanced stages when curative treatment is no longer possible.
CapsoVision (搜索), Inc. (NASDAQ: CV) announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Breakthrough Device Designation (BDD) for its CapsoCam UGI (搜索) capsule endoscopy system to enable early-stage pancreatic cancer (搜索) detection. The application was submitted on November 6, 2025, marking a significant milestone in the company's mission to expand capsule-based diagnostics beyond the small bowel.
The commercial-stage medical technology company is pursuing the potential use of its CapsoCam UGI (搜索) endoscopy to identify pancreatic disease at an earlier stage through its unique panoramic imaging capability. The device enables clear visualization of the duodenal papilla (搜索), a small bowel landmark that controls release of digestive fluids. Changes in the papilla's appearance can be associated with pancreatic abnormalities and may serve as an early indicator of disease.
Addressing Critical Unmet Medical Need
Pancreatic ductal adenocarcinoma (搜索) — the most common form of pancreatic cancer (搜索) — is among the deadliest cancers worldwide, with a five-year survival rate of only 8%. The disease is now the third leading cause of cancer-related death in the United States, despite accounting for just over 3% of all cancer cases. This poor prognosis is largely attributed to late-stage diagnosis, as approximately 80% of diagnoses occur at advanced stages when the disease is already unresectable or metastatic, leaving limited options for curative treatment.
Currently, no early screening tools are recommended to identify the disease at a treatable stage in the general population. Existing diagnostic methods including CT, MRI, and endoscopic ultrasound are invasive, costly, and lack the sensitivity needed to detect small or early-stage lesions. Early detection can improve survival more than fourteen-fold, yet no non-invasive screening method for the general population is currently recommended.
Non-Invasive Technology Platform
Unlike traditional endoscopic or imaging procedures, CapsoCam UGI (搜索) is completely non-invasive. Patients simply swallow a pill-sized camera, eliminating the need for sedation, intubation, or recovery time, while enabling physicians to review detailed images through a secure, cloud-based system. The device offers panoramic imaging of the upper gastrointestinal tract and enables visualization of the duodenal papilla (搜索) — a structure linked to early pancreatic changes.
Regulatory Pathway and Development Strategy
The FDA's Breakthrough Devices Program is designed to expedite the development and review of technologies that may offer more effective diagnosis or treatment for life-threatening conditions where no adequate alternatives exist. If granted, the designation would allow CapsoVision (搜索) to work closely with the FDA to accelerate development and shape upcoming clinical studies, leading the regulatory review process.
The breakthrough designation would allow CapsoVision (搜索) to work more closely with the FDA on device development, clinical trials and regulatory review. This represents an important milestone in CapsoVision's mission to expand its capsule-based diagnostics platform beyond the small bowel and address some of the most challenging diseases in gastroenterology.
Company Pipeline and Platform
CapsoVision (搜索) is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus (搜索)®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The company's next pipeline product, CapsoCam Colon (搜索)™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection.
With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision (搜索) is advancing a new era in capsule-based diagnostics. The submission represents the company's commitment to addressing the urgent global need for innovative, patient-friendly diagnostic technologies that can visualize pancreatic abnormalities earlier, before symptoms emerge and while curative treatment is still possible.